A practical reference on AOD-9604: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
=== Cancer === Specific SNPs are associated with an elevated risk of lung cancer and interact with folate dietary intake in this etiology. The (MTRR):c.66A>G mutation relates to a significant increase in the risk of lung cancer. When co-expressed with the polymorphism (MTR): 2756A>G, lung cancer risk is further increased in a dose dependent manner. Correlation between this polymorphism and increased risk of lung cancer is present with low folate intake and high vitamin B12, suggesting a B12 independent mechanism of action. This mutation is also associated with an increased risk in colorectal cancer, acute lymphoblastic leukemia, bladder cancer, cervical intraepithelial neoplasia, non-Hodgkin lymphoma and esophageal squamous cell carcinoma.
The urban population and infrastructure fell into ruin, together with most peasant farms, whose inhabitants were subjected to increasingly extreme forms of serfdom. The development of science, culture and education came to a halt or regressed.
== Development == The usual development of CAD is when a cool high-pressure area wedges in east of a north-south oriented mountain chain. As a system approaches from the west, a persistent cloud deck with associated precipitation forms and lingers across the region for prolonged periods of time. Temperature differences between the warmer coast and inland sections east of the terrain can exceed 36 degrees Fahrenheit (20 degrees Celsius), with rain near the coast and frozen precipitation, such as snow, sleet, and freezing rain, falling inland during colder times of the year. In the Northern Hemisphere, two-thirds of such events occur between October and April, with summer events preceded by the passage of a backdoor cold front. In the Southern Hemisphere, they have been documented to occur between June and November. Cold air damming events which occur when the parent surface high-pressure system is relatively weak, with a central pressure below 1,028.0 millibars (30.36 inHg), or remaining a progressive feature (move consistently eastward), can be significantly enhanced by cloudiness and precipitation itself. Clouds and precipitation act to increase sea level pressure in the area by 1.5 to 2.0 mb ( 0.04 to 0.06 inHg). When the surface high moves offshore, the precipitation itself can cause the CAD event.
Sources: en.wikipedia.org
=== Mechanism === RIP causes G:C to A:T transition mutations within repeats, however, the mechanism that detects the repeated sequences is unknown. RID is the only known protein essential for RIP. It is a DNA methyltransferease-like protein, that when mutated or knocked out results in loss of RIP. Deletion of the rid homolog in Aspergillus nidulans, dmtA, results in loss of fertility while deletion of the rid homolog in Ascobolus immersens, masc1, results in fertility defects and loss of methylation induced premeiotically (MIP).
where ζ is the potential across the Stern layer (zeta potential), E is the electric field strength, and η is the viscosity of the solvent. Separation of components in CEC is based on interactions between the stationary phase and differential electrophoretic migration of solutes.
A bone growth factor is a growth factor that stimulates the growth of bone tissue. Known bone growth factors include insulin-like growth factor-1 (IGF-1), insulin-like growth factor-2 (IGF-2), transforming growth factor beta (TGF-β), fibroblast growth factors (FGFs), platelet-derived growth factor (PDGF), parathyroid hormone-related peptide (PTHrP), bone morphogenetic proteins (BMPs), and certain members of the growth differentiation factor (GDF) group of proteins. The ultimate target of bone growth factors are osteoblasts, osteoclasts and fibroblasts. Human fibroblasts and osteoblasts were shown to be capable of producing bone growth factors after stimulation. Major hormones influencing bone growth and morphology include growth hormone (GH), androgens such as testosterone and dihydrotestosterone, and estrogens such as estradiol.
Sources: en.wikipedia.org
== F == Fire pits – indigenous peoples throughout the Americas constructed fire pits, or hearths, for cooking, warmth, light, socializing, and tool manufacturing. Archaeological evidence of fire pits in the Americas dates back over 12,000 years; a hearth discovered at the Utah Test and Training Range containing tools, a spear tip, and tobacco seeds was dated to approximately 12,300 years ago, representing some of the earliest inhabitants of the Great Basin. Indigenous Americans developed sophisticated variations of the fire pit, including earth ovens, stone-lined pits used for slow-roasting plant bulbs such as camas, sotol, and agave, which represented a major dietary innovation during the Archaic period. Fire pits were also used for thousands of years to heat-treat stones for tool manufacturing, making them stronger and less likely to fracture, and later for firing pottery. The clambake, developed by indigenous peoples of the Atlantic seaboard such as the Wampanoag, uses a type of earth oven built on a beach with heated rocks, seaweed, and shellfish; early European settlers adopted and elaborated this practice from coastal indigenous peoples. In the Andes, the huatia earth oven, used to roast freshly harvested potatoes and other tubers over hot stones buried under earth, is a pre-Inca tradition that continues to be practiced as a communal celebration after the potato harvest.
The four substrates of this enzyme are phthalic acid, nicotinamide adenine dinucleotide (NADH), oxygen, and a proton. Its products are cis-4,5-dihydroxycyclohexa-2,6-diene-1,2-dicarboxylic acid and NAD+. This enzyme belongs to the family of oxidoreductases, specifically those acting on paired donors, with molecular oxygen as oxidant and incorporation or reduction of oxygen. The systematic name of its class is phthalate,NADH:oxygen oxidoreductase (4,5-hydroxylating). Other names in common use include PDO, and phthalate dioxygenase. The enzyme participates in 2,4-dichlorobenzoate degradation. It is an Iron-sulfur protein which uses flavin mononucleotide as a cofactor.
=== Early life and musical beginnings === Bobby Liebling was the only child of Joseph Liebling, a high-ranking official in the U.S. Department of Defense under President Richard Nixon, and Diane, who had a background as a nightclub singer. He grew up in Washington, D.C., where his father worked as deputy assistant to the secretary of defense. Bobby was raised in a Jewish background. In the 2000s, he converted to Christianity, although, as of 2015, he considers himself spiritual rather than religious. From an early age, Liebling showed a strong interest in music. He started his first band, Shades of Darkness, at 11 years old, performing at school dances. By his teenage years, he was heavily influenced by underground and proto-metal bands such as the Groundhogs, Sir Lord Baltimore, and Stray. On December 25, 1971, Liebling co-founded the band Pentagram with former schoolmate Geof O'Keefe (drums), Vincent McAllister (guitar), and Greg Mayne (bass). He wrote his first songs in his room, playing on a $12 Silvertone guitar. During his late teens, Liebling also began using drugs, including highly pure Cambodian heroin brought back by Vietnam War veterans. His struggles with addiction would later become a defining aspect of his life and career.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.